{
  "id": 5361065,
  "title": "Climb Bio slips after early-stage trial data for kidney disease drug",
  "url": "https://urgent.news/2026/09/03/climb-bio-slips-after-early-stage-trial-data-for-kidney-disease-drug",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-03T16:11:38.000Z",
  "source": {
    "name": "Seeking Alpha News",
    "slug": "seeking-alpha-news",
    "url": "https://seekingalpha.com/news/4639924-climb-bio-rises-trial-data-kidney-drug?feed_item_type=news"
  },
  "original_language": "en",
  "account": null,
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Baird raises Climb Bio stock price target to $25 on trial data",
        "url": "https://urgent.news/2026/09/03/baird-raises-climb-bio-stock-price-target-to-25-on-trial-data",
        "published": "2026-09-03T17:03:05.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}